SHERIDAN, Wyo., Aug. 23, 2022 — Ageless Biotech (ABT), Inc., a biotech company created to bring Stem Cell-based Therapeutics to market, is excited to have Simon Med Imaging, one of the major players within the healthcare and biotech research fields, helping to advance its U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND) for the treatment of Osteoarthritis of the Knee. [Read more…]
Overcoming major challenges in cardiac drug discovery using human induced pluripotent stem cell technology
Highlights
- The biggest opportunity for success in cardiac drug discovery and development is to make these processes more efficient and affordable, since they carry relatively higher risk of clinical trial failure compared to other disciplines.
- Human iPSC technology is increasingly utilized to develop disease models that reliably mimic the diversity of patient pathogenicity and disease severity in vitro.
- Phenotypic screening based on iPSC-derived disease models is making cardiac drug discovery more time and cost effective by enabling target-agnostic studies and increasing the translational power of early drug discovery outcomes.
Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma
LA JOLLA, CALIF (August 2, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a phase 1 physician-sponsored clinical trial that will use Calidi’s licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7 (NeuroNova), a cutting-edge therapeutic candidate comprising tumor-tropic neural stem cells delivering an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma (Calidi’s NNV-2 program). [Read more…]
PeptiGrowth Inc. is Launching A Novel Synthetic Peptide BMP4,7 inhibitor (Noggin-like peptide)
July 26, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide “BMP4,7 inhibitor (Noggin-like peptide)” which binds to several Bone Morphogenetic Proteins (BMPs) to inhibit its activity like Noggin. It will be marketing this product from July, 2022. [Read more…]
Stemmatters, a Portuguese Integrated Therapeutics Developer and Cell Therapy CDMO
Stemmatters is a Portuguese contract development and manufacturing (CDMO) organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices.
In the interview below, we explore Stemmatters history, services, manufacturing facilities, and future goals. Enjoy! [Read more…]
- « Previous Page
- 1
- …
- 145
- 146
- 147
- 148
- 149
- …
- 338
- Next Page »